Login to Your Account



TKT's Replagal Fails Phase III; Genzyme Still Mum On Its Data

By Randall Osborne


Monday, December 2, 2002
As Transkaryotic Therapies Inc. revealed a weak hand regarding Replagal (agalsidase alfa), all eyes turned to competitor Genzyme General, which has been playing its cards close to the vest. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription